MAP3K2 and posterior cortical atrophy: We also tested whether inhibition of the pathway downstream of MAP3K2 similarly altered the properties of PCa cells using BVD-523 (ulixertinib) (41), a catalytic ERK1/2 inhibitor (ERKi).